Skip to main content
. 2020 Jun 19;2020:8024124. doi: 10.1155/2020/8024124

Table 3.

Eligibility criteria for overall survival benefit with ramucirumab, cabozantinib, and regorafenib as the second line of treatment for HCC.

Main
 Male patients
 ECOG: 0
 Extrahepatic metastases
 HBV infection

Independent
 Age
 Alpha-fetoprotein
 Macrovascular invasion